| Income Statement | 2025-06-30 | |||
|---|---|---|---|---|
| Research and development | 537,428 | |||
| Intangible asset impairment | - | |||
| Goodwill impairment | 170,419,429 | |||
| General and administrative | 17,880,050 | |||
| Depreciation and amortization | 129,095 | |||
| Total operating expenses | -188,966,002 | |||
| Loss from operations | -188,966,002 | |||
| Interest expense | -725,684 | |||
| Loss on extinguishment of debt | - | |||
| Change in fair value of equity securities | -112,149 | |||
| Interest income and other income (expense) | 116,346 | |||
| Change in fair value of contingent consideration | 11,680,000 | |||
| Total other income (expense) | 10,958,513 | |||
| Net loss | -178,007,489 | |||
| Basic net loss per common share | -1.08 | |||
| Diluted net loss per common share | -1.08 | |||
| Weighted average number of shares of common stock outstanding - basic | 165,061,967 | |||
| Weighted average number of shares of common stock outstanding - diluted | 165,061,967 | |||
Lunai Bioworks Inc. (RENB)
Lunai Bioworks Inc. (RENB)